Autoimmune Diseases — Systemic Overview: SLE, Scleroderma, Sjögren's, and Vasculitis

Systemic autoimmune diseases represent a complex group of disorders characterized by the immune system's inappropriate attack on the body's own tissues. These conditions affect multiple organ systems simultaneously and are distinguished by the presence of specific autoantibodies, each serving as both diagnostic markers and pathogenic mediators.

The pathophysiology involves a breakdown of immune tolerance, leading to the production of autoantibodies against nuclear antigens (ANAs), cytoplasmic components, and cell surface molecules. This process is triggered by a combination of genetic predisposition, environmental factors, and molecular mimicry. The HLA system plays a crucial role, with specific alleles conferring increased susceptibility to different autoimmune conditions.

Type II and Type III hypersensitivity reactions predominate in these diseases. Type II involves direct antibody-mediated cellular destruction, while Type III results from immune complex deposition in tissues, leading to complement activation and inflammatory cascades. The complement system, particularly the classical pathway, becomes chronically activated, contributing to tissue damage and perpetuating the inflammatory response.

Epigenetic modifications, including DNA methylation and histone acetylation, influence gene expression patterns that predispose to autoimmunity. Environmental triggers such as viral infections (particularly EBV and CMV), UV radiation, silica exposure, and certain medications can initiate disease in genetically susceptible individuals through molecular mimicry or epitope spreading.

The female predominance (F:M ratio 9:1 for SLE) suggests hormonal influences, particularly estrogen's role in promoting Th2 responses and B-cell activation. This hormonal influence explains the frequent disease onset during reproductive years and potential flares during pregnancy or with estrogen-containing medications.

SLE is the prototypical systemic autoimmune disease, affecting virtually every organ system through immune complex deposition and direct autoantibody effects. The 2019 EULAR/ACR classification criteria emphasize the importance of positive ANA testing as an entry criterion, followed by weighted clinical and immunologic criteria.

Clinical Manifestations by System:

Antibody Profile and Clinical Correlations:

• Anti-dsDNA: Highly specific (95%), correlates with disease activity and lupus nephritis. Levels fluctuate with disease flares.
• Anti-Sm: Highly specific (99%) but less sensitive (30%). Associated with renal and neurologic involvement.
• Anti-SSA/Ro52 and Ro60: Associated with photosensitive rashes, neonatal lupus, and congenital heart block in offspring.
• Anti-SSB/La: Often concurrent with anti-Ro, associated with sicca symptoms and neonatal lupus.
• Anti-RNP: Associated with mixed connective tissue disease features, Raynaud's phenomenon.
• Antiphospholipid antibodies: Anticardiolipin, anti-β2-glycoprotein I, and lupus anticoagulant; associated with thrombotic events and pregnancy complications.

Complement levels (C3, C4, CH50) are typically decreased during active disease due to consumption through immune complex formation. Low complement with high anti-dsDNA strongly suggests lupus nephritis requiring urgent evaluation.

Systemic sclerosis (SSc) is characterized by excessive collagen deposition, vasculopathy, and immune system activation. The disease follows a triphasic pattern: inflammatory, fibrotic, and atrophic phases. Two major subtypes exist based on skin involvement extent and autoantibody profiles.

Limited Cutaneous SSc (lcSSc):

• Skin involvement distal to elbows/knees and face
• CREST syndrome: Calcinosis, Raynaud's, Esophageal dysmotility, Sclerodactyly, Telangiectasias
• Associated with anticentromere antibodies (ACA)
• Better prognosis, later onset of internal organ involvement
• Pulmonary arterial hypertension (PAH) is the leading cause of death

Diffuse Cutaneous SSc (dcSSc):

• Skin involvement proximal to elbows/knees, trunk
• Associated with anti-topoisomerase I (Scl-70) antibodies
• Rapid progression with early internal organ involvement
• Interstitial lung disease and scleroderma renal crisis are major complications

Pathophysiology involves three key processes:

1. Vasculopathy: Endothelial injury leads to vessel wall thickening, luminal narrowing, and microinfarcts
2. Fibrosis: TGF-β overproduction stimulates excessive collagen synthesis by activated myofibroblasts
3. Immune activation: T-cell activation and autoantibody production perpetuate tissue damage

Additional Antibody Associations:

• Anti-RNA polymerase III: Associated with dcSSc, scleroderma renal crisis, and malignancy
• Anti-PM/Scl: Associated with myositis-scleroderma overlap syndrome
• Anti-U1-RNP: Mixed connective tissue disease features
• Anti-fibrillarin (U3-RNP): Severe skin and pulmonary involvement, more common in African Americans

Capillaroscopy reveals characteristic changes: enlarged capillary loops, hemorrhages, and avascular areas. These findings help differentiate primary from secondary Raynaud's phenomenon and predict disease progression.

Sjögren's syndrome (SS) is a chronic autoimmune disorder primarily affecting exocrine glands, leading to sicca symptoms (dry eyes and mouth). However, it frequently presents with significant systemic manifestations affecting multiple organ systems.

Primary vs. Secondary Sjögren's:

• Primary SS: Isolated glandular and systemic autoimmune features
• Secondary SS: Occurs in association with other autoimmune diseases (RA, SLE, SSc)

Pathophysiology: Lymphocytic infiltration of salivary and lacrimal glands leads to acinar cell destruction and functional impairment. The inflammatory infiltrate consists predominantly of CD4+ T-cells and B-cells organized into ectopic germinal centers. This process is mediated by pro-inflammatory cytokines (IL-1, TNF-α, IFN-γ) and chemokines.

Clinical Manifestations:

Antibody Profile:

• Anti-SSA/Ro52 and Ro60: Present in 70% of patients, associated with systemic features, neonatal lupus, and extraglandular manifestations
• Anti-SSB/La: Present in 50%, associated with earlier disease onset and more severe glandular dysfunction
• Rheumatoid Factor (RF): Positive in 90%, often high-titer
• Anti-centromere: Associated with limited skin involvement and pulmonary hypertension

Diagnostic Approach: The 2016 ACR/EULAR classification criteria include objective signs of ocular/oral dryness, autoantibody positivity, and characteristic histopathology (focus score ≥1 on minor salivary gland biopsy). Schirmer's test (<5mm/5min) and unstimulated whole saliva flow (<0.1mL/min) provide objective measures of glandular dysfunction.

ANCA-associated vasculitides (AAV) are a group of systemic necrotizing vasculitides affecting small to medium-sized vessels. The classification is based on clinical phenotypes and ANCA patterns, with significant diagnostic and therapeutic implications.

Classification of AAV:

1. Granulomatosis with Polyangiitis (GPA, formerly Wegener's)

   • Upper and lower respiratory tract involvement with necrotizing granulomatous inflammation
   • Necrotizing glomerulonephritis
   • c-ANCA/PR3-ANCA positive in 90% of generalized disease

2. Microscopic Polyangiitis (MPA)

   • Necrotizing vasculitis without granulomatous inflammation
   • Pulmonary capillaritis and glomerulonephritis predominate
   • p-ANCA/MPO-ANCA positive in 70-80%

3. Eosinophilic Granulomatosis with Polyangiitis (EGPA, formerly Churg-Strauss)

   • Asthma, eosinophilia, and vasculitis
   • Two phenotypes: ANCA-positive (MPO) with more vasculitic features, ANCA-negative with more allergic/eosinophilic features

ANCA Testing and Interpretation:

Pathophysiology: ANCA antibodies activate neutrophils through Fc receptor engagement and complement activation, leading to degranulation and release of cytotoxic enzymes. This process is enhanced by priming stimuli such as infections or pro-inflammatory cytokines. The activated neutrophils adhere to endothelial cells, causing direct cytotoxicity and triggering the coagulation cascade.

Laboratory Monitoring:

• ANCA titers: May correlate with disease activity in some patients, but serial monitoring has limited utility
• Complement levels: Usually normal, helping differentiate from immune complex diseases
• Urinalysis: Essential for detecting glomerulonephritis (proteinuria, hematuria, red cell casts)
• Inflammatory markers: ESR and CRP are elevated during active disease

Tissue diagnosis remains crucial as ANCA positivity alone is insufficient for diagnosis. Biopsy shows necrotizing inflammation with minimal immune deposits ("pauci-immune").

Antinuclear antibodies represent a diverse group of autoantibodies directed against various nuclear and cytoplasmic antigens. ANA testing serves as a crucial screening tool for systemic autoimmune diseases, with specific patterns providing diagnostic clues.

ANA Testing Methodology:

Immunofluorescence Patterns on HEp-2 Cells:

ANA Titers and Clinical Significance:

• 1:80-1:160: Low positive, may be seen in healthy individuals (5-10%)
• 1:320-1:640: Moderate positive, suggests autoimmune disease
• ≥1:1280: High positive, strongly associated with systemic autoimmune disease

Specific Antibody Testing (ENA Panel): Following positive ANA screening, specific antibody testing helps refine diagnosis:

Anti-dsDNA Testing:

• Crithidia luciliae immunofluorescence (high specificity)
• ELISA methods (higher sensitivity, lower specificity)
• Farr assay (radioimmunoassay, gold standard)

Extractable Nuclear Antigens (ENA):

• Multiplex assays allow simultaneous testing for multiple specificities
• Line immunoassays provide semi-quantitative results
• Individual ELISA tests for confirmation of positive results

Clinical Approach to ANA Results:

1. Negative ANA: Makes SLE unlikely (sensitivity >95%), but doesn't exclude other autoimmune diseases
2. Positive ANA: Requires clinical correlation and specific antibody testing
3. Pattern recognition: Guides selection of specific antibody tests
4. Serial monitoring: ANA titers don't reliably correlate with disease activity

False Positives and Pitfalls:

• Age-related increase in ANA positivity
• Medication-induced positivity (hydralazine, procainamide, anti-TNF agents)
• Infections (EBV, hepatitis, endocarditis)
• Malignancy-associated ANA
• Technical factors affecting interpretation

The diagnosis of systemic autoimmune diseases requires integration of clinical features, laboratory findings, and sometimes histopathologic confirmation. A systematic approach helps avoid both over-diagnosis and missed diagnoses.

General Diagnostic Approach:

Clinical Suspicion of Autoimmune Disease ↓ ANA Screening ↓ Positive ← → Negative ↓ ↓ Specific Ab Consider: Testing - ANCA-associated vasculitis ↓ - Seronegative disease Pattern-based - Alternative diagnoses Antibody Panel ↓ Clinical Correlation + Organ-specific testing

Disease-Specific Diagnostic Criteria:

SLE (2019 EULAR/ACR Criteria):

• Entry criterion: ANA ≥1:80
• Weighted criteria (constitutional, hematologic, neuropsychiatric, mucocutaneous, serosal, musculoskeletal, renal, immunologic)
• Score ≥10 with at least one clinical criterion

Systemic Sclerosis (2013 ACR/EULAR Criteria):

• Skin thickening proximal to MCPs = 9 points (sufficient)
• Additional weighted criteria: fingertip lesions, telangiectasias, abnormal capillaroscopy, PAH/ILD, Raynaud's, SSc-specific antibodies
• Score ≥9 classifies as SSc

Laboratory Monitoring Strategies:

Differential Diagnosis Considerations:

Overlap Syndromes:

• Mixed Connective Tissue Disease (MCTD): Anti-U1-RNP positive
• Antisynthetase syndrome: Anti-Jo-1 and related antibodies
• Rhupus: RA-SLE overlap

Mimickers to Consider:

• Fibromyalgia (chronic pain without objective findings)
• Malignancy (paraneoplastic syndromes)
• Infections (endocarditis, chronic viral infections)
• Drug-induced autoimmune syndromes
• Primary immunodeficiencies

Red Flags Requiring Urgent Evaluation:

• Rapidly progressive glomerulonephritis
• Pulmonary-renal syndrome
• Neuropsychiatric symptoms
• Scleroderma renal crisis
• Signs of secondary malignancy

Interdisciplinary Management: Successful management requires coordination between rheumatology, nephrology, pulmonology, dermatology, and other specialists based on organ involvement patterns.

Treatment of systemic autoimmune diseases follows a stratified approach based on disease severity, organ involvement, and individual patient factors. The goal is to achieve remission while minimizing medication toxicity through careful monitoring and dose optimization.

Treatment Hierarchy:

First-line Agents:

• Hydroxychloroquine: Universal in SLE, antimalarial with anti-inflammatory and antithrombotic effects
• Methotrexate: Anchor DMARD for arthritis and skin manifestations
• Corticosteroids: For disease flares and organ-threatening manifestations

Second-line Immunosuppressants:

• Mycophenolate mofetil: Preferred for lupus nephritis maintenance
• Azathioprine: Alternative immunosuppressant, requires TPMT testing
• Cyclophosphamide: Reserved for severe organ involvement (nephritis, CNS lupus, severe vasculitis)

Biologic Therapies:

• Belimumab: B-cell targeted therapy for SLE
• Rituximab: CD20 depletion for refractory disease
• Tocilizumab: IL-6 inhibition for systemic sclerosis-associated ILD

Organ-Specific Approaches:

Monitoring Requirements:

Laboratory Monitoring:

• Complete blood count: Weekly initially, then monthly for immunosuppressants
• Comprehensive metabolic panel: Monitor renal function and electrolytes
• Liver function tests: Essential for MTX, AZA, and other hepatotoxic agents
• Urinalysis: Critical for detecting nephritis in SLE and AAV

Specialized Monitoring:

• Ophthalmologic screening: Annual for hydroxychloroquine retinopathy
• Bone density: Baseline and follow-up for chronic steroid use
• Infection screening: Before initiating immunosuppression (TB, hepatitis B/C, HIV)
• Vaccination status: Live vaccines contraindicated during immunosuppression

Pregnancy Considerations: Many immunosuppressants are teratogenic, requiring careful planning:

• Safe medications: Hydroxychloroquine, sulfasalazine, azathioprine, certain biologics
• Contraindicated: Methotrexate, cyclophosphamide, mycophenolate
• Neonatal lupus monitoring: For anti-Ro/La positive mothers

Emergency Scenarios:

• Scleroderma renal crisis: ACE inhibitors, avoid corticosteroids
• Lupus nephritis flare: Urgent nephrology consultation, consider pulse steroids
• Pulmonary-renal syndrome: Immediate immunosuppression with cyclophosphamide
• Thrombotic events: Anticoagulation for antiphospholipid syndrome